Prospects of MMX Mesalazine in Routine Outpatient Treatment of Ulcerative Colitis
Aim. A general review of treatment approaches to ulcerative colitis (UC) and the importance of oral 5-aminosalicylic acid (5-ASA) for its routine outpatient management.Key points. The choice of drug therapy for UC remission induction and maintenance is linked to the intestinal lesion extent and dise...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Gastro LLC
2022-03-01
|
| Series: | Российский журнал гастроэнтерологии, гепатологии, колопроктологии |
| Subjects: | |
| Online Access: | https://www.gastro-j.ru/jour/article/view/606 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823860121216745472 |
|---|---|
| author | Yu. P. Uspenskiy S. V. Ivanov Yu. A. Fominykh |
| author_facet | Yu. P. Uspenskiy S. V. Ivanov Yu. A. Fominykh |
| author_sort | Yu. P. Uspenskiy |
| collection | DOAJ |
| description | Aim. A general review of treatment approaches to ulcerative colitis (UC) and the importance of oral 5-aminosalicylic acid (5-ASA) for its routine outpatient management.Key points. The choice of drug therapy for UC remission induction and maintenance is linked to the intestinal lesion extent and disease attack severity. The 5-ASA therapy remains the mainstay UC treatment in routine outpatient practice, with prescription rate of 80–90%. Oral 5-ASA drugs are often used in monotherapy or when oral and rectal 5-ASAs are recommended in combination. As a sustained-release medication, the MMX mesalazine multi-matrix delivery system provides for higher active substance dosages along entire colonic mucosa, including its distal portions. A higher active substance dosage per tablet reduces the number of intakes and ensures a better patient adherence, both in terms of daily and long-term therapy.Conclusion. The 5-ASA drugs are most commonly prescribed in outpatient practice. Sustained-release 5-ASAs provide for a more effective active ingredient distribution at higher dosages along colonic mucosa. |
| format | Article |
| id | doaj-art-3b8d1d98eb5d41f9be4c2ebd263c230d |
| institution | Kabale University |
| issn | 1382-4376 2658-6673 |
| language | Russian |
| publishDate | 2022-03-01 |
| publisher | Gastro LLC |
| record_format | Article |
| series | Российский журнал гастроэнтерологии, гепатологии, колопроктологии |
| spelling | doaj-art-3b8d1d98eb5d41f9be4c2ebd263c230d2025-02-10T16:14:37ZrusGastro LLCРоссийский журнал гастроэнтерологии, гепатологии, колопроктологии1382-43762658-66732022-03-0131671510.22416/1382-4376-2021-31-6-7-15455Prospects of MMX Mesalazine in Routine Outpatient Treatment of Ulcerative ColitisYu. P. Uspenskiy0S. V. Ivanov1Yu. A. Fominykh2Saint-Petersburg State Pediatric Medical University; Pavlov First Saint-Petersburg State Medical UniversityPavlov First SaintPetersburg State Medical University; Saint-Petersburg State Pediatric Medical UniversitySaint Petersburg State Pediatric Medical University; Pavlov First Saint-Petersburg State Medical UniversityAim. A general review of treatment approaches to ulcerative colitis (UC) and the importance of oral 5-aminosalicylic acid (5-ASA) for its routine outpatient management.Key points. The choice of drug therapy for UC remission induction and maintenance is linked to the intestinal lesion extent and disease attack severity. The 5-ASA therapy remains the mainstay UC treatment in routine outpatient practice, with prescription rate of 80–90%. Oral 5-ASA drugs are often used in monotherapy or when oral and rectal 5-ASAs are recommended in combination. As a sustained-release medication, the MMX mesalazine multi-matrix delivery system provides for higher active substance dosages along entire colonic mucosa, including its distal portions. A higher active substance dosage per tablet reduces the number of intakes and ensures a better patient adherence, both in terms of daily and long-term therapy.Conclusion. The 5-ASA drugs are most commonly prescribed in outpatient practice. Sustained-release 5-ASAs provide for a more effective active ingredient distribution at higher dosages along colonic mucosa.https://www.gastro-j.ru/jour/article/view/606ulcerative colitis5-aminosalicylic acidmesalazinemmx mesalazine |
| spellingShingle | Yu. P. Uspenskiy S. V. Ivanov Yu. A. Fominykh Prospects of MMX Mesalazine in Routine Outpatient Treatment of Ulcerative Colitis Российский журнал гастроэнтерологии, гепатологии, колопроктологии ulcerative colitis 5-aminosalicylic acid mesalazine mmx mesalazine |
| title | Prospects of MMX Mesalazine in Routine Outpatient Treatment of Ulcerative Colitis |
| title_full | Prospects of MMX Mesalazine in Routine Outpatient Treatment of Ulcerative Colitis |
| title_fullStr | Prospects of MMX Mesalazine in Routine Outpatient Treatment of Ulcerative Colitis |
| title_full_unstemmed | Prospects of MMX Mesalazine in Routine Outpatient Treatment of Ulcerative Colitis |
| title_short | Prospects of MMX Mesalazine in Routine Outpatient Treatment of Ulcerative Colitis |
| title_sort | prospects of mmx mesalazine in routine outpatient treatment of ulcerative colitis |
| topic | ulcerative colitis 5-aminosalicylic acid mesalazine mmx mesalazine |
| url | https://www.gastro-j.ru/jour/article/view/606 |
| work_keys_str_mv | AT yupuspenskiy prospectsofmmxmesalazineinroutineoutpatienttreatmentofulcerativecolitis AT svivanov prospectsofmmxmesalazineinroutineoutpatienttreatmentofulcerativecolitis AT yuafominykh prospectsofmmxmesalazineinroutineoutpatienttreatmentofulcerativecolitis |